Insanity of left ventricular assist therapy: doing the same thing and expecting different results.

James Antaki
The success or failure of left ventricular assist device (LVAD) therapy can be measured in several ways. The landmark clinical trials, REMATCH1 and INTrEPID,2defined success in terms of mortality and morbidity, compared with standard medical therapy. Indeed, these are the primary benchmarks used by the US Food and Drug Agency when evaluating a device for market approval. On a grander scale, success may be measured in terms of the popularity or use of the therapy....
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.